Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Rasheda Ali, Stem Cell Advocate and Muhammad Ali’s Daughter, Visits with Hadassah’s Neurology Experts

Rasheda Ali in Hadassah's GMP facility.

Rasheda Ali, daughter of the legendary boxer, Muhammad Ali and member of the advisory board of BrainStorm, the Israeli company that works on innovative treatments for Parkinson's and Multiple Sclerosis with Hadassah Senior Neurologist Prof. Dimitrios Karussis, will now focus her efforts on behalf of the BrainStorm/Hadassah methodology.

Prof. Karussis (middle) and Prof. Ben Hur explain a brain imaging scan.

Ms. Ali visited the Hadassah Medical Center this summer with the managers of BrainStorm, where she met with Prof. Dimitrios Karussis, Director of Hadassah's Multiple Sclerosis Center, and Prof. Tamir Ben-Hur, head of Neurology.

The two professors described their work involving the autologous transplant of mesenchymal stem cells to treat degenerative brain diseases. They explained the importance of collaborating with the bio-tech industry—BrainStorm specifically—and what their next steps will be. Ms. Ali, an internationally known advocate for research into degenerative brain diseases, has personal experience with this debilitating decline of brain function, since her father, Muhammad, suffers from Parkinson's.

During her visit to Hadassah, Chaim Lebovitz, President of BrainStorm, and Adrian Harel, Chief Executive Officer, took Ms. Ali to see Hadassah's GMP (Good Manufacturing Product) research laboratory, where the collaborative work of BrainStorm and Hadassah is performed. Highly impressed with what she witnessed, Ms. Ali was glad to be able to meet the physicians behind the names she had come to know.

Date: 8/9/2012

More hMedicine Stories

Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America